Latest

Oct 31, 2016
By Pharmaceutical Executive Editors
Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week.
Oct 24, 2016
FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.
Oct 12, 2016
Pharmaceutical Executive
The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.
Aug 31, 2016
For generic firms, Inter Partes Reviews (IPRs) are a cost-effective way to clear out FDA Orange Book-listed patents before or during litigation; for originator companies, they pose a threat to valuable patent portfolios. Steve Maebius reports.
Aug 24, 2016
Traditional sales and pricing practices face legal challenges and political backlash, writes Jill Wechsler.
Jul 27, 2016
Stakeholders are looking to move up the Prescription Drug User Fee Act timeframe to gain Congressional action before the Obama administration steps down.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
Jul 07, 2016
Patients are buried in content, so it is a must to grab a share of the narrow bandwidths that they possess, writes Casey McDonald
Jun 30, 2016
FDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.
Jun 21, 2016
Rapid growth in Medicare spending on prescription drugs is prompting a leading advisory group to recommend significant revisions in how the government pays for medicines under Part D and Part B
native1_300x100
lorem ipsum